25
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      TGF-β drives epithelial-mesenchymal transition through δEF1-mediated downregulation of ESRP

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Epithelial-mesenchymal transition (EMT) is a crucial event in wound healing, tissue repair and cancer progression in adult tissues. We have recently shown that transforming growth factor (TGF)-β-induced EMT involves isoform switching of fibroblast growth factor receptors by alternative splicing. We performed a microarray-based analysis at single exon level to elucidate changes in splicing variants generated during TGF-β-induced EMT, and found that TGF-β induces broad alteration of splicing patterns by downregulating epithelial splicing regulatory proteins (ESRPs). This was achieved by TGF-β-mediated upregulation of δEF1 family proteins, δEF1 and SIP1. δEF1 and SIP1 each remarkably repressed ESRP2 transcription through binding to the ESRP2 promoter in NMuMG cells. Silencing of both δEF1 and SIP1, but not either alone, abolished the TGF-β-induced ESRP repression. The expression profiles of ESRPs were inversely related to those of δEF1 and SIP in human breast cancer cell lines and primary tumor specimens. Further, overexpression of ESRPs in TGF-β-treated cells resulted in restoration of the epithelial splicing profiles as well as attenuation of certain phenotypes of EMT. Therefore, δEF1 family proteins repress the expression of ESRPs to regulate alternative splicing during TGF-β-induced EMT and the progression of breast cancers.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: found
          • Article: not found

          Epithelial-mesenchymal transitions in development and disease.

          The epithelial to mesenchymal transition (EMT) plays crucial roles in the formation of the body plan and in the differentiation of multiple tissues and organs. EMT also contributes to tissue repair, but it can adversely cause organ fibrosis and promote carcinoma progression through a variety of mechanisms. EMT endows cells with migratory and invasive properties, induces stem cell properties, prevents apoptosis and senescence, and contributes to immunosuppression. Thus, the mesenchymal state is associated with the capacity of cells to migrate to distant organs and maintain stemness, allowing their subsequent differentiation into multiple cell types during development and the initiation of metastasis.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Understanding alternative splicing: towards a cellular code.

            In violation of the 'one gene, one polypeptide' rule, alternative splicing allows individual genes to produce multiple protein isoforms - thereby playing a central part in generating complex proteomes. Alternative splicing also has a largely hidden function in quantitative gene control, by targeting RNAs for nonsense-mediated decay. Traditional gene-by-gene investigations of alternative splicing mechanisms are now being complemented by global approaches. These promise to reveal details of the nature and operation of cellular codes that are constituted by combinations of regulatory elements in pre-mRNA substrates and by cellular complements of splicing regulators, which together determine regulated splicing pathways.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Splicing in disease: disruption of the splicing code and the decoding machinery.

              Human genes contain a dense array of diverse cis-acting elements that make up a code required for the expression of correctly spliced mRNAs. Alternative splicing generates a highly dynamic human proteome through networks of coordinated splicing events. Cis- and trans-acting mutations that disrupt the splicing code or the machinery required for splicing and its regulation have roles in various diseases, and recent studies have provided new insights into the mechanisms by which these effects occur. An unexpectedly large fraction of exonic mutations exhibit a primary pathogenic effect on splicing. Furthermore, normal genetic variation significantly contributes to disease severity and susceptibility by affecting splicing efficiency.
                Bookmark

                Author and article information

                Journal
                Oncogene
                Oncogene
                Oncogene
                Nature Publishing Group
                0950-9232
                1476-5594
                28 June 2012
                31 October 2011
                : 31
                : 26
                : 3190-3201
                Affiliations
                [1 ]simpleDepartment of Molecular Pathology, Graduate School of Medicine, University of Tokyo , Tokyo, Japan
                [2 ]simpleSection of Oral Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University , Tokyo, Japan
                [3 ]simpleDepartment of Life Science and Medical Bio-Science, Waseda University , Tokyo, Japan
                [4 ]simpleFirst Department of Surgery, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi , Yamanashi, Japan
                [5 ]simpleDepartment of Biochemistry, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi , Yamanashi, Japan
                Author notes
                [* ]simpleDepartment of Molecular Pathology, Graduate School of Medicine, University of Tokyo , 7-3-1 Hongo, Bunkyo-ku, Tokyo 113 0033, Japan. E-mail: miyazono@ 123456m.u-tokyo.ac.jp or msaitoh-ind@ 123456umin.ac.jp
                Article
                onc2011493
                10.1038/onc.2011.493
                3391666
                22037216
                b0b4acf2-caa9-46af-a0af-9182e00936b0
                Copyright © 2012 Macmillan Publishers Limited

                This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

                History
                : 06 April 2011
                : 25 July 2011
                : 15 September 2011
                Categories
                Original Article

                Oncology & Radiotherapy
                esrp,tgf-β,alternative splicing,δef1,breast cancer,emt
                Oncology & Radiotherapy
                esrp, tgf-β, alternative splicing, δef1, breast cancer, emt

                Comments

                Comment on this article